NLS Pharmaceutics and Kadimastem Move Closer to Merger Approval

NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem (TASE: KDST) have reached a key milestone in their planned merger after Kadimastem’s shareholders approved the deal in a special general meeting. The merger aims to create a Nasdaq-listed biotechnology company with a strong portfolio of treatments for neurodegenerative diseases and diabetes.

NLS is now preparing to hold its own shareholder meeting for final approval. If completed, the merger will combine the expertise of both companies, leveraging NLS’s innovative drug development capabilities and Kadimastem’s advancements in cell therapy.

Kadimastem’s CEO, Ronen Twito, expressed confidence in the merger’s potential to create value for shareholders by uniting the strengths of both companies. NLS CEO Alex Zwyer echoed this sentiment, emphasizing their commitment to advancing groundbreaking therapies.

With both firms focused on addressing unmet medical needs, the merger could position them as a major player in biotechnology. The coming weeks will determine the final outcome as NLS seeks its shareholders’ approval.

You might like this article: Novo Nordisk Soars on Promising Results for New Weight Loss Drug